Fagron's extensive SyrSpend® SF oral suspension stability study list continues to expand to new API’s

Fri, 09/02/2016

Fagron's extensive SyrSpend® SF oral suspension stability study list continues to expand to new API’s

Fagron recognizes our compounding customers’ need to have quality stability and BUD data to support their efforts is creating customized medications. A recent PubMed search resulted in numerous SyrSpend® SF products that have been published in reputable peer reviewed journals, including 5 of the top 10 drugs administered according to 2014 CMS utilization data covering 38 million beneficiaries enrolled in Medicare Part D.1 As of September 1, 2016, there is peer reviewed published stability data for 27 API’s with SyrSpend® SF products that directly match the standard drug concentrations for compounded oral liquids developed for pediatric patients in Michigan.2 Fagron’s goal is to provide the healthcare community with ongoing quality research and data to support compounding customized medications.

 

1https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-08-18.html 
  
2http://www.mipedscompounds.org/